Expert Q&A: Medical Affairs in the Precision Medicine Era - Navigating Complexity, Enabling Progress

Medical affairs teams are a crucial link between advanced science and clinical practice in precision medicine. Not just data sharers, they integrate genomic, biomarker and clinical insights in close collaboration with researchers and healthcare professionals (HCPs) to translate complex molecular data into personalized treatment strategies to benefit diverse patient populations.

FirstWord spoke with Svetlana Kobina, vice president of oncology global and US medical affairs at AbbVie, about how the role of medical affairs is evolving in precision medicine, the associated opportunities and challenges, and how AbbVie is addressing them to enhance patient outcomes.

Key Questions Answered:

• How has precision medicine changed the role of medical affairs at AbbVie?
• What are the biggest challenges in managing and analysing the large datasets required for precision medicine?
• How does medical affairs facilitate collaboration among researchers, HCPs and regulatory bodies in precision medicine?
• What strategies do you use to effectively communicate complex scientific data to HCPs and patients?
• What are the key regulatory challenges in developing and implementing precision medicines?
• How does AbbVie address ethical concerns related to precision medicine, such as accessibility and affordability?
• How does AbbVie ensure HCPs are adequately trained to implement precision medicine in clinical practice?
• What role do medical affairs professionals play in ongoing education and training for clinicians?
• What future trends do you foresee in precision medicine, and how is AbbVie preparing for them?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.